Dermatol. praxi. 2018;12(4):196-198 | DOI: 10.36290/der.2018.045
Long-term omalizumab therapy in a patient with severe chronic spontaneous urticaria
- Kožní oddělení, Masarykova nemocnice v Ústí nad Labem, o.z., Krajská zdravotní, a. s.
Case report describes long-term cyclic therapy with omalizumab in a young patient with a severe form of chronic spontaneousurticaria (CSU), not responding to the treatment of increased dose H1-antihistamines and the corticosteroid therapy. The patienthas completed 6 cycles of therapy during last two years, each with an excellent effect.
Keywords: omalizumab, monoclonal anti‑IgEantibody, chronic spontaneous urticaria (CSU)
Received: November 28, 2017; Accepted: November 29, 2017; Published: December 1, 2018 Show citation
References
- Lynde C, et al. Omalizumab Retreatment of Patients With Chronic Idiopathic Urticaria / Chronic Spontaneous Urticaria Following Return of Symptoms: Primary Results of the OPTIMA Study. Presented at the 26th Congress of the European Academy of Dermatology and Venereology (EADV), 13-17 September 2017.
- Maurer M, Rosén K, Hsin-Ju Hsieh, et al. Omalizumab for the treatment of Chronic Idiopatic or spontaneous Urticaria, N.Engl.J.Med.,2013; 368: 924-925.
Go to original source... 
Go to PubMed... - Nettis E, at al. Efficacy and rapid activity of omalizumab retreatment in chronic spontaneous urticaria, Journal of the American Academy of Dermatology, 2018 Vol. 78, Issue 6, p1211-1213. Go to original source... Go to PubMed...
- Zuberbier T, Aberer W, Asero R, et al. International EAACI/GA2LEN/EDF/WAO guidelines for the definition, classification, diagnosis and management of urticaria the 2013 revision un update: Allergy 2014; 69: 868-887. Go to original source... Go to PubMed...